Cargando…
Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review
This systematic review evaluated the animal and human evidence for pharmacomicrobiomics (PMx) interactions of antidepressant medications. Studies of gut microbiota effects on functional and behavioral effects of antidepressants in human and animal models were identified from PubMed up to December 20...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381387/ https://www.ncbi.nlm.nih.gov/pubmed/37511699 http://dx.doi.org/10.3390/jpm13071086 |
_version_ | 1785080431242117120 |
---|---|
author | Brown, Lisa C. Bobo, William V. Gall, Cory A. Müller, Daniel J. Bousman, Chad A. |
author_facet | Brown, Lisa C. Bobo, William V. Gall, Cory A. Müller, Daniel J. Bousman, Chad A. |
author_sort | Brown, Lisa C. |
collection | PubMed |
description | This systematic review evaluated the animal and human evidence for pharmacomicrobiomics (PMx) interactions of antidepressant medications. Studies of gut microbiota effects on functional and behavioral effects of antidepressants in human and animal models were identified from PubMed up to December 2022. Risk of bias was assessed, and results are presented as a systematic review following PRISMA guidelines. A total of 28 (21 animal, 7 human) studies were included in the review. The reviewed papers converged on three themes: (1) Antidepressants can alter the composition and metabolites of gut microbiota, (2) gut microbiota can alter the bioavailability of certain antidepressants, and (3) gut microbiota may modulate the clinical or modeled mood modifying effects of antidepressants. The majority (n = 22) of studies had at least moderate levels of bias present. While strong evidence is still lacking to understand the clinical role of antidepressant PMx in human health, there is evidence for interactions among antidepressants, microbiota changes, microbiota metabolite changes, and behavior. Well-controlled studies of the mediating and moderating effects of baseline and treatment-emergent changes in microbiota on therapeutic and adverse responses to antidepressants are needed to better establish a potential role of PMx in personalizing antidepressant treatment selection and response prediction. |
format | Online Article Text |
id | pubmed-10381387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103813872023-07-29 Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review Brown, Lisa C. Bobo, William V. Gall, Cory A. Müller, Daniel J. Bousman, Chad A. J Pers Med Systematic Review This systematic review evaluated the animal and human evidence for pharmacomicrobiomics (PMx) interactions of antidepressant medications. Studies of gut microbiota effects on functional and behavioral effects of antidepressants in human and animal models were identified from PubMed up to December 2022. Risk of bias was assessed, and results are presented as a systematic review following PRISMA guidelines. A total of 28 (21 animal, 7 human) studies were included in the review. The reviewed papers converged on three themes: (1) Antidepressants can alter the composition and metabolites of gut microbiota, (2) gut microbiota can alter the bioavailability of certain antidepressants, and (3) gut microbiota may modulate the clinical or modeled mood modifying effects of antidepressants. The majority (n = 22) of studies had at least moderate levels of bias present. While strong evidence is still lacking to understand the clinical role of antidepressant PMx in human health, there is evidence for interactions among antidepressants, microbiota changes, microbiota metabolite changes, and behavior. Well-controlled studies of the mediating and moderating effects of baseline and treatment-emergent changes in microbiota on therapeutic and adverse responses to antidepressants are needed to better establish a potential role of PMx in personalizing antidepressant treatment selection and response prediction. MDPI 2023-06-30 /pmc/articles/PMC10381387/ /pubmed/37511699 http://dx.doi.org/10.3390/jpm13071086 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Brown, Lisa C. Bobo, William V. Gall, Cory A. Müller, Daniel J. Bousman, Chad A. Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review |
title | Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review |
title_full | Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review |
title_fullStr | Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review |
title_full_unstemmed | Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review |
title_short | Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review |
title_sort | pharmacomicrobiomics of antidepressants in depression: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381387/ https://www.ncbi.nlm.nih.gov/pubmed/37511699 http://dx.doi.org/10.3390/jpm13071086 |
work_keys_str_mv | AT brownlisac pharmacomicrobiomicsofantidepressantsindepressionasystematicreview AT bobowilliamv pharmacomicrobiomicsofantidepressantsindepressionasystematicreview AT gallcorya pharmacomicrobiomicsofantidepressantsindepressionasystematicreview AT mullerdanielj pharmacomicrobiomicsofantidepressantsindepressionasystematicreview AT bousmanchada pharmacomicrobiomicsofantidepressantsindepressionasystematicreview |